# CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B Cells as predictors of humoral response to COVID-19 mRNA vaccination in immunocompromised patients

Eduard Schulz<sup>1\*</sup>, Isabel Hodl<sup>2\*</sup>, Patrick Forstner<sup>3</sup>, Stefan Hatzl<sup>1</sup>, Nazanin Sareban<sup>4</sup>, Martina Moritz<sup>4</sup>, Johannes Fessler<sup>5</sup>, Barbara Dreo<sup>2</sup>, Barbara Uhl<sup>1</sup>, Claudia Url<sup>4</sup>, Andrea Grisold<sup>3</sup>, Michael Khalil<sup>6</sup>, Barbara Kleinhappl<sup>3</sup>, Christian Enzinger<sup>6</sup>, Martin H. Stradner<sup>2</sup>, Hildegard Greinix<sup>1</sup>, Peter Schlenke<sup>4</sup> and Ivo Steinmetz<sup>3</sup>

\*ES and IH contributed equally to the manuscript.

<sup>1</sup>Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria <sup>2</sup>Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

<sup>3</sup>Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria

<sup>4</sup>Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria

<sup>5</sup>Institute of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria <sup>6</sup>Department of Neurology, Medical University of Graz, Graz, Austria

Corresponding author:

Martin H. Stradner Division of Rheumatology and Immunology Department of Internal Medicine Medical University of Graz Auenbruggerplatz 15, 8036 Graz, Austria Tel: +43/316/385-81794 Fax: +43/316/385-17813 E-mail: martin.stradner@medunigraz.at

The authors declare no competing financial interests.

Key words: mRNA vaccine, COVID-19, B cells, cancer, immunodeficiency

#### ABSTRACT

Immunocompromised patients are considered high-risk and prioritized for vaccination against COVID-19. We aimed to analyze B-cell subsets in these patients to identify potential predictors of humoral vaccination response. Patients (n=120) suffering from hematologic malignancies or other causes of immunodeficiency and healthy controls (n=79) received a full vaccination series with an mRNA vaccine. B-cell subsets were analyzed prior to vaccination. Two independent anti-SARS-CoV-2 immunoassays targeting the receptor-binding domain (RBD) or trimeric S protein (TSP) were performed three to four weeks after the second vaccination. Seroconversion occurred in 100% of healthy controls, in contrast to 67% (RBD) and 82% (TSP) of immunocompromised patients, while only 32% (RBD) and 22% (TSP) achieved antibody levels comparable to those of healthy controls. The number of circulating CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B cells was strongly associated with antibody levels ( $\rho$ =0.761, P<0.001) and the only independent predictor for achieving antibody levels comparable to healthy controls (OR 1.07 per 10-µl increase, 95%CI 1.02–1.12, P=0.009). Receiver operating characteristic analysis identified a cut-off at ≥61 naïve B cells per µl to discriminate between patients with and without an optimal antibody response. Consequently, measuring naïve B cells in immunocompromised hematologic patients could be useful in predicting their humoral vaccination response.

#### **INTRODUCTION**

2 Coronavirus disease 2019 (COVID-19) results in increased morbidity and mortality in 3 immunocompromised patients.(1-3) Immunodeficiency can be primary (PID) due to underlying genetic 4 causes such as common variable immunodeficiency or secondary (SID) resulting from hematologic 5 malignancies (HM), immunosuppressive therapies, or hematopoietic stem cell transplantation (HSCT). 6 In a recent study of 100 patients with COVID-19 disease, patients with PID and SID demonstrated 7 higher morbidity and mortality than the general population, while the outcomes of individuals suffering 8 from SID were the worst.(1) In patients with HM and COVID-19, a mortality rate of 34% (95% 9 confidence interval [CI]: 28-39) has been reported in adults in a recent meta-analysis including 3377 10 predominantly hospitalized patients from 3 continents.(4) Interestingly, patients on systemic anticancer 11 treatment had a similar risk of death compared to patients without therapy (RR 1.17, 95% CI: 0.83-1.64). 12 Risk of death was highest in patients with acquired bone marrow failure syndromes (53%, 95% CI: 34-13 72), followed by acute leukemias (41%, 95% CI: 30-52), myeloproliferative neoplasms (34%, 95% CI: 14 19-51), plasma cell dyscrasias (33%, 95% CI: 25-41), lymphomas (32%, 95% CI: 18-48), and chronic lymphocytic leukemias (CLL) (31%, 95% CI: 23-40), respectively. 15

16 Patients with HM can be immunocompromised due to the underlying malignancy itself, prior or ongoing 17 treatments with a high degree of immunosuppressive effects such as corticosteroids, B-cell depleting 18 therapies, HSCT and other cellular therapies. In individuals with these risk factors, lower rates of 19 seroconversion have been reported after COVID-19 infection whereas other cancer patients developed 20 antibody response similar to healthy individuals.(5, 6) Roeker and colleagues observed that 67% of 21 patients with CLL developed IgG antibodies to SARS-CoV-2 nucleocapsid and the seroconversion rate 22 among recipients of HSCT and chimeric antigen receptor (CAR) T-cell therapy was similar at 66%.(7, 8) 23

Due to the high risk of severe COVID-19 in immunocompromised patients, they are considered a high priority for COVID-19 vaccination.(9-13) However, trials of the currently approved COVID-19 vaccines have excluded individuals diagnosed with immunodeficiency or malignancy; therefore, information on the efficacy and safety of the vaccines in these patients is sparse.(14-17) It is well known that vaccinations in patients early after HSCT and anti-CD20 therapies as well as with several forms of PID have low efficacy.(18-20) The humoral immune response to a recombinant zoster vaccine in patients with B-cell lymphoma and CLL was between 20% and 50% compared to 80% in patients with other HM.(21)

Lack of antibody responses after COVID-19 vaccination and significantly lower antibody levels in responders have been reported in HM patient cohorts in general(5, 22, 23) and in selected patients with multiple myeloma, CLL, and non-Hodgkin's lymphoma.(24-28) Low efficacy of COVID-19 vaccinations was observed when administered soon after HSCT and anti-CD20 therapies.(9, 18, 19) Furthermore, immunocompromised patients due to inborn errors of immunity or autoimmune rheumatic disease (AIRD) demonstrated also reduced rates in seroconversion, especially when given B-celldepleting therapy and glucocorticoids.(14-17)

39 Peripheral B cells are needed for humoral vaccination responses.(29) However, the number of 40 circulating B cells or of a certain B-cell subset associated with a humoral vaccination response 41 comparable to healthy individuals is unknown. A marker predictive of vaccination response would aid 42 to schedule vaccinations in the immunocompromised patients to achieve an optimal vaccination 43 response.

We hypothesize that specific B-cell subsets have to be present in immunocompromised individuals to
enable a humoral vaccination response. Herein, we used data from an interim analysis of the prospective,
open-label, phase IV CoVVac trial (NCT04858607) to test this hypothesis.

#### 47 MATERIALS AND METHODS

#### 48 Study design and participants

We report the data of an interim analysis of the CoVVac trial (NCT04858607), which is an ongoing open-label, phase IV, prospective, monocentric study at the Medical University of Graz, Austria. After approval by the ethics committee of the Medical University of Graz in April 2021 (EK 1128/2021), patients with inborn errors of immunity, hematological malignancies, those receiving B-cell-depleting therapy, and healthy controls were recruited before receiving their first dose of COVID-19 vaccine. The detailed study protocol is provided in the Supplementary Information. In brief, blood was drawn before the first vaccination with BNT162b2 (BioNTech/Pfizer) or mRNA-1273 (Moderna) for peripheral blood mononuclear cell (PBMC) isolation and lymphocyte phenotyping. The second vaccination was administered 21 (BNT162b2) or 28 days (mRNA-1273) after the first. Blood sampling was performed 21–28 days after the second vaccination to analyze the COVID-19-specific antibody response as the primary endpoint.

## 60 Lymphocyte phenotyping

61 Blood samples from the baseline visit were processed within 4 hours for analysis by flow cytometry. 62 For lymphocyte phenotyping, ethylenediaminetetraacetic acid whole blood was stained for CD3, CD4, CD8, CD45, CD16, CD56, and CD19, as previously described.(30) For B-cell phenotyping, PBMCs 63 were isolated from lithium heparin whole blood by Ficoll gradient density centrifugation. One million 64 PBMCs were incubated with the following antibodies: CD19-VioGreen, anti-IgD-VioBlue, CD24-65 66 PerCP-Vio700, CD38-FITC, CD27-APC, CD86-PE-Vio770, CD21-APC-Vio770, and anti-IgM-PE 67 (Miltenyi Biotec, Bergisch Gladbach, Germany). Samples were measured using a FACSLyric flow 68 cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Data were analyzed using the FACSSuite (BD 69 Biosciences). The gating strategy is shown in Supplemental Figure 1.

#### 70 Antibody assays

71 Blood was obtained before first and 21–28 days after the second vaccination. Serum was aliquoted, 72 frozen, and stored at -80°C until analysis was performed in batches. Two commercially available CE-73 certified serological tests were performed according to the manufacturers' protocols to determine and 74 quantify specific antibodies against SARS-CoV-2. Specific IgG was determined using the Roche Elecsys anti-SARS-CoV-2 S electrochemiluminescence immunoassay targeting the receptor-binding 75 76 domain of the viral spike protein using a Cobas e 801 analytical unit (Roche Diagnostics GmbH, 77 Mannheim, Germany).(27, 29) Its quantification range lies between 0.4 and 2500 U/ml, with a cut-off of 0.8 U/ml for positivity. Specific IgG was measured by Liaison SARS-CoV-2 TrimericS IgG test on 78 79 Liaison XL (DiaSorin, Saluggia, Italy), which is a chemiluminescence immunoassay quantifying 80 antibodies that target the trimeric S protein.(28) Results are provided in binding antibody units (BAU)

81 with a quantification range of 4.81-2080 BAU/ml. Values  $\geq 33.8$  BAU/ml were considered positive.

#### 82 Statistical analysis

All statistical analyses were performed using Stata 16.1 (Stata Corp., Houston, TX, USA). Continuous 83 84 data were reported as medians (25th-75th percentile) and categorical data as absolute frequencies (%). Correlations and associations between antibody response and other variables were examined using 85 Spearman's rank-based correlation coefficients, rank-sum test, and  $\chi^2$ -squared tests. R<sup>2</sup>-statistics were 86 87 obtained from multiple linear regression models with antibody response as the dependent variable. The 88 optimal cut-off to separate patients with and without vaccination response was assessed by employing 89 a maximized Youden's index within a receiver operating characteristic (ROC) analysis. Logistic models 90 were used for univariate and multivariate modeling of the vaccination response. The Kruskal-Wallis 91 test was used for continuous variables when comparing three or more treatment groups. The Kruskal-92 Wallis H test was used as a post-hoc test to determine between-group differences.

### 93 **RESULTS**

#### 94 Study population

Data of 199 study participants who completed their full vaccination schedule were included in the 95 efficacy analysis. Of these, 79 were healthy participants and 120 were immunocompromised patients. 96 97 All study participants were vaccinated with mRNA-1273, with only two healthy individuals (1%) 98 receiving BNT162b2. A total of 140 adverse events occurred after vaccination, with the most common 99 being pain at the injection site, headache, fever, and fatigue. Four severe adverse events (hospitalization 100 and death due to HM and bone fractures) were considered unrelated to vaccination. Participant 101 characteristics are listed in Table 1. Diagnoses, immunosuppressive treatments, and antibody responses 102 for subgroups are detailed in Supplementary Table 1.

103

104

Variable	Healthy (n=79)	Immunocompromised (n=120)	Р	
Age (years)	51 [36-56]	58 [50-65]	<0.001	
Female gender n (%)	45 (57)	65 (54)	0.698	
Body mass index (kg/m <sup>2</sup> )	23.7 [21.6-26.4]	24.8 [22.7-27.8]	0.039	
Vaccine			0.080	
mRNA-1273 (Moderna)	77 (97)	120 (100)		
BNT162b2 (BioNTech/Pfizer)	2 (3)	0 (0)		
Immunodeficiency group			n/a	
Primary immunodeficiency n (%)		25 (21)		
Autoimmune disease n (%)		39 (32)		
Hematologic disease n (%)		56 (47)		
B-cell depleting therapy			n/a	
None n (%)		44 (37)		
Rituximab n (%)		35 (29)		
Ocrelizumab n (%)		6 (5)		
HSCT n (%)		35 (29)		
Days since B-cell depletion		166 [69-545]		

#### 106 Table 1.

107

Table 1. Baseline characteristics of the study population. Data are reported as medians [25th-108 75th percentile] and absolute frequencies (%). P-values are from rank-sum tests,  $\chi^2$ -tests, and Fisher's 109 exact tests, as appropriate. Significant P-values are highlighted in bold type. Abbreviations: n, number;

110 HSCT, hematopoietic stem cell transplantation

#### Immunogenicity of mRNA vaccines 111

112 Antibody responses were assessed using two different assays. All healthy controls demonstrated 113 seroconversion with high antibody titers (Roche median: 2500 U/ml; DiaSorin median: 2080 BAU/ml). In immunocompromised patients, the seroconversion rates and antibody levels were significantly lower 114 than those in healthy controls (Table 2 and Figure 1); 67% (n = 80) and 82% (n = 98) of patients 115 116 demonstrated a humoral response with antibody levels within the quantification range of Roche and DiaSorin assays, respectively. Since the clinical significance of antibody levels close to the limit of 117 detection was unclear, we defined more stringent thresholds for our patients, namely a "stringent 118 response" as reaching at least the lowest antibody level of the healthy individuals from our cohort (Roche 119 120 ≥1000 U/ml; DiaSorin ≥2000 BAU/ml). According to this definition, only 32% (Roche) and 22%

(DiaSorin) of patients had a stringent antibody response. This difference was not statistically significant 121 122 between the two tests (P = 0.108). Patients who received anti-CD20 therapy, including the majority of 123 patients with AIRD, had the lowest rate of stringent response ( $\leq 10\%$ ). Interestingly, patients who 124 received HSCT demonstrated a relatively high rate of stringent response [37% (13/35)]. There was no statistically significant difference between allogeneic and autologous HSCT (40% vs. 30%, respectively; 125 126 P = 0.541). The antibody levels of both assays showed an excellent correlation with each other in the patient population ( $\rho = 0.915$ , P<0.001, R<sup>2</sup> = 0.841; Table 2; Figure 2A), as well as in the entire study 127 128 population (Supplementary Figure 2A). Since the Roche assay is more widely used in research and shows a good correlation with live virus neutralization tests in vaccinated individuals(22, 27, 29, 31), 129 we focused on the Roche assay for subsequent analyses to ensure comparability with other studies. 130

131 **Table 2.** 

	Healthy (n=79) N (%)	Immunocompromised (n=120) N (%)	Р
Roche any response	79 (100)	80 (67)	<0.001
Roche stringent response	79 (100)	38 (32)	<0.001
Roche U/ml	2500 [2500-2500]	67 [0-1947]	<0.001
DiaSorin any response	79 (100)	98 (82)	<0.001
DiaSorin stringent response	79 (100)	26 (22)	<0.001
DiaSorin BAU/ml	2080 [2080-2080]	233 [12-1760]	<0.001

132Table 2.Antibody Response to Vaccination. Data are reported as medians [25th-75th percentile]133and absolute frequencies (%). P-values are from rank-sum tests,  $\chi^2$ -tests, and Fisher's exact tests, as134appropriate. Significant P-values are highlighted in bold type. Any response, any seroconversion; BAU,135binding antibody unit; DiaSorin stringent response, DiaSorin SARS-CoV-2 TrimericS IgG  $\geq$ 2000136BAU/ml; HSCT, hematopoietic stem stell transplantation; Roche stringent response, Roche anti-SARS-137CoV-2 S total antibody titer  $\geq$ 1000 U/ml.

#### 139 Correlation of antibody levels with the amount of B-cell subsets

140 The total number of B cells and all B-cell subsets prior vaccination were positively correlated with the 141 antibody levels in all patients (Roche:  $\rho = 0.739$ ,  $R^2 = 0.001$ , P<0.001; Table 3; Figure 2B). In this 142 analysis, the absolute number of naïve B cells showed the highest correlation with antibody titers (Roche:  $\rho = 0.761$ ,  $R^2 = 0.153$ ; Figure 2C). Furthermore, this analysis also indicated that the time 143 between last B-cell-depleting therapy and vaccination was also a significant factor correlating with 144 antibody levels. Extending this correlation analysis to the entire study population (Supplementary Figure 145 2), the influence of naïve B cells remained highly significant (Roche:  $\rho = 0.636$ , P<0.001, R<sup>2</sup> = 0.123). 146 To support the results of our correlation analyses, we established a model of stringent vaccination 147 148 response prediction for the entire study population based on the results of the Roche assay using the area 149 under the ROC curve (AUC; Supplementary Table 2). This model suggests that the total number of 150 CD19<sup>+</sup> B cells (AUC: 0.87, 95% CI: 0.79–0.92), CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B cells (AUC: 0.82, 95% CI: 151 0.73-0.88), CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>+</sup> pre-switched memory B cells (AUC: 0.84, 95% CI: 0.76-0.89), and CD19<sup>+</sup>IgD<sup>-</sup>CD27<sup>+</sup> switched memory B cells (AUC: 0.85, 95% CI: 0.79–0.91) can predict response to 152 vaccination in the entire study population. 153

156

Variable	Roche anti-SARS-CoV-2		
	ρ	Р	R <sup>2</sup>
DiaSorin SARS-CoV-2 TrimericS IgG	0.915	<0.001	0.841
Age	0.091	0.321	0.001
Body mass index	0.169	0.076	0.004
Days since last B-cell depletion	0.595	<0.001	0.041
Interval in days from last B-cell depleting therapy to vaccination up to 365 days	0.481	0.001	0.096
IgA	0.042	0.651	0.015
IgG	0.065	0.481	0.031
IgM	0.386	<0.001	0.002
Lymphocytes abs.	0.222	0.018	0.002
CD3 <sup>+</sup> cells abs.	0.112	0.236	0.034
CD3 <sup>+</sup> CD8 <sup>+</sup> cells abs.	0.170	0.071	0.005
CD3 <sup>+</sup> CD4 <sup>+</sup> cells abs.	0.025	0.789	0.062
CD3 <sup>-</sup> CD16 <sup>+</sup> CD56 <sup>+</sup> NK cells abs.	-0.014	0.880	0.014
CD19 <sup>+</sup> abs.	0.739	<0.001	0.001
CD45 <sup>+</sup> cells abs.	0.227	0.015	0.002
CD19 <sup>+</sup> IgM <sup>+</sup> CD38 <sup>++</sup> transitional B cells abs.	0.491	<0.001	0.033
CD19 <sup>+</sup> IgD <sup>+</sup> CD27 <sup>-</sup> naïve B cells abs.	0.761	<0.001	0.153
CD19 <sup>+</sup> IgD <sup>+</sup> CD27 <sup>+</sup> pre-switched memory B cells abs.	0.657	<0.001	0.004
CD19 <sup>+</sup> IgD <sup>-</sup> CD27 <sup>+</sup> switched memory B cells abs.	0.710	<0.001	0.003
CD19 <sup>+</sup> CD38 <sup>-</sup> CD21 <sup>-</sup> B cells abs.	0.640	<0.001	0.001
CD19 <sup>+</sup> IgM <sup>-</sup> CD38 <sup>++</sup> plasmablasts abs.	0.580	<0.001	0.001

157 immunocompromised study population. Correlations were computed with Spearman's rank-based rho 158 adjusted for multiple testing (n=21) with Šidák correction. The Šidák-adjusted  $\alpha$  level is approximately 159 0.00244. Significant P-values are highlighted in bold type. Abs., absolute count.

## 161 CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B cells show the strongest association with

#### 162 stringent response

163 To test the association of variables with vaccination response determined by the Roche assay, we 164 performed univariate and multivariate linear regression analyses using the same variables from the 165 correlation analyses.

166 In univariate analysis (Table 4), the variables found to be significantly associated with any antibody 167 response in patients included interval in days from the last B-cell-depleting therapy, CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> 168 naïve B-cell count, CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>+</sup> pre-switched memory B-cell count, and absolute number of 169 CD19<sup>+</sup>IgM<sup>-</sup>CD38<sup>++</sup> plasmablasts. The same correlation was also found for stringent antibody responses, 170 except for the correlation with CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>+</sup> pre-switched memory B cells. The absolute number 171 of these B-cell subsets was significantly lower in immunocompromised patients than in healthy controls, 172 in patients after anti-CD20 antibody therapy compared to HSCT, and in patients without seroconversion compared to those with any antibody response (not shown) or stringent response (Supplementary Figure 173 3). Immunoglobulin levels and cell counts of immunodeficient patients stratified by vaccination 174 175 response are shown in Supplementary Table 3. In univariate analysis of the entire study population 176 (Supplementary Table 4), the same B-cell subsets remained significantly associated with vaccine 177 response.

In multivariable analysis for stringent response, only the number of CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B cells was an independent predictor (OR: 1.07 per 10- $\mu$ l increase, 95% CI: 1.02–1.12, P = 0.009). The only independent predictor of any seroconversion was CD19<sup>+</sup>IgM<sup>-</sup>CD38<sup>++</sup> plasmablast count (OR: 4.42 per 1- $\mu$ l increase, 95% CI: 1.30–15.01, P = 0.017).

The multivariable analyses for the entire study population are shown in Supplementary Tables 5 and 6.
The absolute number of CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B cells remained an independent predictor of stringent
antibody response (OR: 1.14 per 10-µl increase, 95% CI: 1.08–1.20, P<0.001).</li>

# **Table 4.**

Variable	Any Response			Stringe	Stringent Response		
	OR	95% CI	Р	OR	95% CI	Р	
Age (per 10 years)	1.23	0.92-1.66	0.167	1.02	0.76-1.38	0.880	
Body mass index (per 5 point)	1.20	0.77-1.87	0.420	1.11	0.71-0.73	0.633	
Interval in days from last B-cell depleting therapy to vaccination up to 365 days (per 30 days)*	1.41	1.13-1.76	0.002	1.31	1.02-1.67	0.035	
IgA (per 1g/l)	0.74	0.50-1.10	0.136	1.30	0.87-1.93	0.199	
IgG (per 5g/l)	0.96	0.62-1.49	0.848	1.43	0.90-2.27	0.127	
IgM (per 1g/l)	1.32	0.83-2.10	0.246	0.98	0.92-1.05	0.677	
Lymphocytes abs. (per 1 G/l)	0.94	0.81-1.10	0.461	1.03	0.89-1.18	0.686	
$CD3^+$ cells abs. (per $10/\mu l$ )	1.00	0.99-1.01	0.693	1.00	0.99-1.01	0.101	
CD3 <sup>+</sup> CD8 <sup>+</sup> cells abs. (per 10/µl)	1.01	0.99-1.02	0.143	1.00	0.99-1.01	0.846	
$\begin{array}{lll} CD3^+CD4^+ & cells & abs.\\ (per 10/\mu l) & \end{array}$	0.99	0.98-1.01	0.403	1.01	1.00-1.02	0.009	
CD3 <sup>-</sup> CD16 <sup>+</sup> CD56 <sup>+</sup> NK cells abs. (per 10/µl)	0.98	0.96-1.01	0.139	1.01	0.99-1.03	0.180	
CD19 <sup>+</sup> abs. (per 10/µl)	0.99	0.99-1.01	0.401	0.99	0.99-1.01	0.931	
$CD45^+$ cells abs. (per $10/\mu l$ )	0.99	0.99-1.01	0.045	1.00	0.99-1.01	0.653	
CD19 <sup>+</sup> IgM <sup>+</sup> CD38 <sup>++</sup> transitional B cells abs. (per 1/µl)	1.17	0.97-1.42	0.094	1.05	0.96-1.15	0.233	
CD19 <sup>+</sup> IgD <sup>+</sup> CD27 <sup>-</sup> naïve B cells abs. (per 10/µl)	1.17	1.07-1.28	0.001	1.09	1.04-1.14	<0.001	
CD19 <sup>+</sup> IgD <sup>+</sup> CD27 <sup>+</sup> pre- switched memory B cells abs. (per 10/µl)	1.78	1.09-2.92	0.021	1.03	0.95-1.11	0.480	

CD19 <sup>+</sup> IgD <sup>-</sup> CD27 <sup>+</sup> switched memory B cells abs. (per 10/µl)	0.99	0.99-1.01	0.406	0.99	0.99-1.00	0.957
CD19 <sup>+</sup> CD38 <sup>-</sup> CD21 <sup>-</sup> B cells abs. (per 10/µl)	0.99	0.98-1.01	0.512	1.00	0.99-1.01	0.746
CD19 <sup>+</sup> IgM <sup>-</sup> CD38 <sup>++</sup> plasmablasts abs. (per 1/µl)	7.95	2.68-23.4	<0.001	1.85	1.24-2.74	0.002

188**Table 4**.Univariate linear regression analysis to test the association of variables with vaccination189response determined by the Roche anti-SARS-CoV-2 S assay in the immunodeficient cohort. Significant190P-values are highlighted in bold type. Any response, any seroconversion; OR, odds ratio; stringent191response, total antibody titer  $\geq 1000$  U/ml. Abs., absolute count.

192

#### 193 **Exploratory analyses**

As CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B cells were the only B-cell subset independently associated with stringent antibody response, we were interested to determine whether our dataset allowed to estimate a CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B cell count threshold for stringent antibody response. ROC analysis and nonlinear risk modeling predicted that  $\geq$ 61 CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B cells per µl discriminated best between patients with and without a stringent vaccine response (Figures 3A, B).

A second exploratory ROC analysis was undertaken to determine the minimum interval between last B-cell-depleting therapy, i.e., anti-CD20 antibody therapy or HSCT up to 365 days (n = 53), and vaccination differentiating any seroconversion versus no vaccination response. The optimal cut-off in this population was 116 days or more (Figure 3C).

#### 203 **DISCUSSION**

Since the presence of B cells is a prerequisite for humoral vaccination responses, we investigated B cells
 overall and multiple B-cell subsets in immunocompromised patients and healthy controls prior to
 COVID-19 mRNA vaccination.

207 Our findings confirm recent reports observing significantly lower and more heterogeneous anti-SARS-208 CoV-2 S protein IgG titers in immunocompromised patients compared to healthy controls.(14, 15, 22, 209 24-29) In one of the largest studies, Maneikis and colleagues reported lower median anti-S1 IgG 210 responses after two BNT162b2 vaccine doses in 653 patients with HM compared to 69 healthy 211 healthcare workers.(23) A similar heterogeneity in vaccination response has been observed in patients 212 with PID,(14) AIRD,(16) and individuals given anti-CD20 therapy.(22, 23, 27, 32) In view of the 213 heterogeneity of anti-SARS-CoV-2 antibody levels and the current lack of knowledge regarding the 214 clinical consequences of low versus high titers in immunocompromised patients, we additionally 215 analyzed stringent vaccination response defined as the lowest anti-SARS-CoV-2 antibody titers 216 observed in our healthy control assuming that these would be protective. Based on this definition, only 217 32% (Roche) and 22% (DiaSorin) of our patients demonstrated a stringent antibody response, 218 respectively. Longitudinal studies are on their way to assess durability of anti-SARS-CoV-2 humoral 219 responses as well as incidences of COVID-19 infections in patients with or without stringent humoral 220 response.

221 In our study, absolute numbers of CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B cells, CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>+</sup> pre-switched 222 memory B cells, and CD19<sup>+</sup>IgM<sup>-</sup>CD38<sup>++</sup> plasmablasts were significantly associated with anti-SARS-CoV-2 response in univariate analysis. However, only the number of CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B 223 224 cells was an independent predictor of a stringent vaccination response in multivariable analysis, 225 suggesting their functional importance for obtaining a humoral immune response. Indeed, the production 226 of specific antibodies to a novel antigen relies on the presence of antigen-specific B cells within the CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B cell population.(33) Thus, a drastically contracted pool of CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> 227 228 naïve B cells reduces the chance of harboring B cells with a B-cell receptor of high antigen avidity that 229 can interact with T follicular helper cells successfully and subsequently undergo somatic hypermutation 230 to develop an optimal antibody response.(34) A lack of these cells results in low antibody titers of poor 231 quality. Therefore, the association of the magnitude of the humoral vaccination response with the 232 abundance of CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B cells is most likely a causal relationship.

To date, there is little literature on this topic, and we are the first to describe this relationship, particularly in the context of COVID-19 and immunocompromised patients. The importance of naïve B cells for 235 antibody response has already been shown for the H5N1 influenza vaccine, but to the best of our 236 knowledge not yet for immunocompromised patient cohorts or COVID-19 in particular.(35) Recently, 237 Redjoul and colleagues reported a significant increase in anti-SARS-CoV-2 antibodies in 42 HM 238 patients given a third dose of BNT162b2 vaccine after allogeneic HSCT.(36) In a multivariable analysis, 239 only a peripheral B-cell count of more than 250/µl at the time of the third vaccination was associated 240 with humoral response (OR 7.1, 95% CI: 1.5-34.1, P=0.016).(36) Mrak et al. observed that the percentage of peripheral CD19<sup>+</sup> B cells positively correlated with antibody levels after BNT162b2 241 242 vaccination ( $\tau$ =0.4, P<0.001) in patients with AIRD after rituximab therapy.[24] The median percentage of peripheral CD19<sup>+</sup> B cells was 2% (interquartile range [IQR], 0-33) in the study of Mrak et al., which 243 244 is not very different from 4% (IQR, 0-13) in our patient population. Our results extend these findings 245 and show that only CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B cells predicted a strong vaccination response.

How soon humoral immune responses may be expected after B-cell depleting therapy remains a concern, and recommendations of medical societies differ. Our data confirm that the interval between the last Bcell-depleting therapy and SARS-CoV-2 vaccination plays a crucial role in achieving seroconversion for immunocompromised patients. We were able to define a minimum of 116 days, i.e. 4 months, from last B-cell-depleting therapy to vaccination as prerequisite for obtaining an anti-SARS-CoV-2 seroconversion.

252 Whereas patients after allogeneic HSCT have high numbers of CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B cells, this 253 B-cell subpopulation was significantly lower in individuals suffering from chronic graft-versus-host 254 disease (GVHD).(37) Long-term clinical efficacy of rituximab could be demonstrated in chronic GVHD 255 patients recovering naïve B cells after treatment. These findings are consistent with clinical responses 256 to rituximab reported in patients with rheumatoid arthritis, SLE, and mixed cryoglobulinemia who 257 recovered B cells.(38-40) Thus, rise in absolute numbers of B cells as well as CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve 258 B cells might indicate immune reconstitution after immunosuppressive therapies enabling achievement 259 of a humoral immune response to SARS-CoV-2 vaccination. Contrarily, patients with a deficit of CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B cells may benefit more from continuation of strict hygiene measures as 260 recommended by scientific organizations. Whether these immunocompromised patients will 261

substantially benefit from a third vaccination, must be demonstrated since first data of HSCT patientsshowed only low antibody titers in half of the patients.(36)

264 Our study had several limitations. These include single-center design and limited representation of some 265 patient cohorts that do not allow clear conclusions on seroconversion rates among less common entities 266 or less frequently used treatment strategies. Moreover, we cannot comment on the persistence of the 267 observed vaccination response at this point. Our study relies on the measurement of antibodies as a surrogate for immunity to SARS-CoV-2. However, our results do not significantly differ between the 268 269 two internationally deployed anti-spike protein serological assays for detecting either total Ig or IgG. 270 Both tests showed a high correlation with surrogate neutralization tests, and Roche's assay correlated well with live virus neutralization tests in vaccinated individuals.(29, 31) The strength of our study is 271 272 its prospective design and the introduction of the stringent vaccination response as a potentially 273 clinically more relevant concept than seroconversion.

In summary, humoral response to SARS-CoV-2 mRNA vaccine is impaired in immunocompromised patients. The abundance of circulating CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B cells is strongly associated with an improved antibody vaccine response across different diseases and therapies. Therefore, measuring CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B cells may allow prediction of a humoral response to COVID-19 vaccination in immunocompromised patients. Further research is needed to confirm these findings for vaccinating immunocompromised individuals against COVID-19 and other pathogens.

#### 280 Acknowledgments

We thank Pia-Carina Gallaun and Julia Lodron for technical assistance. The samples/data used for this
project were processed with the help of the Biobank Graz of the Medical University of Graz, Austria.

#### 283 Competing Interests

None of the contributing authors have a conflict of interest, including specific financial interests,
relationships, and affiliations relevant to the topic or materials covered in the manuscript.

#### 286 Author contributions

287 IH, ES, PS, SH, HG, IS, and MHS designed the study. ES, IH, PF, NS, JF, BD, BU, AG, MM, CU, MK,

288 CE and BK collected clinical samples and/or data. PF and BK performed antibody assays. ES and SH

- analyzed the data and performed the statistical analysis. ES, SH, IH, PS, HG, IS, and MHS critically
- reviewed and discussed the results. ES, IH, PF, HS, HG, and MHS wrote the first draft. All authorsreviewed the draft and approved the final version of the manuscript.

#### 292 **REFERENCES**

- 293 1. Shields AM, Burns SO, Savic S, Richter AG, UK PIN COVID-19 Consortium. COVID-19 in patients
- with primary and secondary immunodeficiency: The United Kingdom experience. J Allergy Clin *Immunol* 2021; 147: 870,875.e1.
- 296 2. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of
- 297 COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet* 2020; **395**: 1907-18.
- 3. Hatzl S, Eisner F, Schilcher G, Kreuzer P, Gornicec M, Eller P, *et al.* Response to "COVID-19 in
  persons with haematological cancers". *Leukemia* 2020; **34**: 2265-70.
- 4. Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, *et al.* Outcomes of patients with
  hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. *Blood* 2020; **136**: 2881-92.
- 5. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, *et al.* Seroconversion
  rates following COVID-19 vaccination among patients with cancer. *Cancer Cell* 2021;.
- 305 6. Marra A, Generali D, Zagami P, Cervoni V, Gandini S, Venturini S, et al. Seroconversion in patients
- 306 with cancer and oncology health care workers infected by SARS-CoV-2. *Ann Oncol* 2021; **32**: 113-9.
- 307 7. Roeker LE, Knorr DA, Pessin MS, Ramanathan LV, Thompson MC, Leslie LA, et al. Anti-SARS-
- 308 CoV-2 antibody response in patients with chronic lymphocytic leukemia. *Leukemia* 2020; **34**: 3047-9.
- 309 8. Shah GL, DeWolf S, Lee YJ, Tamari R, Dahi PB, Lavery JA, et al. Favorable outcomes of COVID-
- 310 19 in recipients of hematopoietic cell transplantation. J Clin Invest 2020; 130: 6656-67.

- 311 9. Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, et al. COVID-19 vaccine-readiness
- for anti-CD20-depleting therapy in autoimmune diseases. *Clin Exp Immunol* 2020; **202**: 149-61.
- 10. Ribas A, Sengupta R, Locke T, Zaidi SK, Campbell KM, Carethers JM, *et al.* Priority COVID-19
  Vaccination for Patients with Cancer while Vaccine Supply Is Limited. *Cancer Discov* 2021; **11**: 2336.
- 316 11. van der Veldt, A A M, Oosting SF, Dingemans AC, Fehrmann RSN, GeurtsvanKessel C, Jalving M,
  317 *et al.* COVID-19 vaccination: the VOICE for patients with cancer. *Nat Med* 2021; 27: 568-9.
- 318 12. Ameratunga R, Longhurst H, Steele R, Lehnert K, Leung E, Brooks AES, et al. Common Variable
- 319 Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic
  320 COVID-19. *J Allergy Clin Immunol Pract* 2021;.
- 321 13. Furer V, Rondaan C, Agmon-Levin N, van Assen S, Bijl M, Kapetanovic MC, *et al.* Point of view
  322 on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases.
  323 *RMD Open* 2021; 7: e001594. doi: 10.1136/rmdopen-2021.
- 14. Hagin D, Freund T, Navon M, Halperin T, Adir D, Marom R, *et al.* Immunogenicity of PfizerBioNTech COVID-19 vaccine in patients with inborn errors of immunity. *J Allergy Clin Immunol* 2021;.
- 326 15. Braun-Moscovici Y, Kaplan M, Braun M, Markovits D, Giryes S, Toledano K, *et al.* Disease activity
  327 and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer
  328 mRNA vaccine against SARS-CoV-2. *Ann Rheum Dis* 2021;.
- 16. Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, *et al.* Immunogenicity and safety
  of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory
  rheumatic diseases and in the general population: a multicentre study. *Ann Rheum Dis* 2021;.
- 17. Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Demissie EG, *et al.* Effect of
  Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective
  Cohort Study. *Ann Intern Med* 2021;.

- 18. Jaffe D, Papadopoulos EB, Young JW, O'reilly RJ, Prockop S, Kernan NA, et al. Immunogenicity
- of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic
  cell (HC) transplants. *Blood* 2006; **108**: 2470-5.
- 338 19. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical
- practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis* 2014; **58**: e44-100.
- 20. Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la Morena, M T,
- *et al.* International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. J *Allergy Clin Immunol Pract* 2016; 4: 38-59.
- 343 21. Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, et al. Immunogenicity and
- 344 safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase
- 345 3, randomised, clinical trial and post-hoc efficacy analysis. *Lancet Infect Dis* 2019; **19**: 988-1000.
- 346 22. Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody
  347 response to SARS-CoV-2 vaccines in patients with hematologic malignancies. *Cancer Cell* 2021;.
- 348 23. Maneikis K, Šablauskas K, Ringelevičiūtė U, Vaitekėnaitė V, Čekauskienė R, Kryžauskaitė L, et al.
- 349 Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients
- with haematological malignancies in Lithuania: a national prospective cohort study. *Lancet Haematol*2021; 8: e583-92.
- 24. Avivi I, Balaban R, Shragai T, Sheffer G, Morales M, Aharon A, *et al.* Humoral response rate and
  predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. *Br J Haematol* 2021;.
- 25. Bird S, Panopoulou A, Shea RL, Tsui M, Saso R, Sud A, *et al.* Response to first vaccination against
  SARS-CoV-2 in patients with multiple myeloma. *Lancet Haematol* 2021; 8: e389-92.

- 26. Gavriatopoulou M, Terpos E, Kastritis E, Briasoulis A, Gumeni S, Ntanasis-Stathopoulos I, *et al.*Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the
  BNT162b2 and AZD1222 vaccine. *Clin Exp Med* 2021;: 1-5.
- 360 27. Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2
- 361 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. *Blood* 2021; **137**: 3165-73.
- 28. Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, *et al.* Fifth-week
  immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma
  and myeloproliferative malignancies on active treatment: preliminary data from a single institution. *J Hematol Oncol* 2021; 14: 81-021.
- 366 29. Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H, Sieghart D, *et al.* SARS-CoV-2
  367 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence
  368 of T-cell-mediated immunity. *Ann Rheum Dis* 2021;.
- 369 30. Stradner MH, Dejaco C, Brickmann K, Graninger WB, Brezinschek HP. A combination of cellular
  biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational
  study. *Arthritis Res Ther* 2016; 18: 190-016.
- 31. Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R, *et al.* AntiSpike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five
  Quantitative Assays. *Microbiol Spectr* 2021;: e0024721.
- 375 32. Herzog Tzarfati K, Gutwein O, Apel A, Rahimi-Levene N, Sadovnik M, Harel L, *et al.* BNT162b2
  376 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. *Am J*377 *Hematol* 2021;.
- 378 33. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. *Nat Rev Immunol*2009; 9: 185-94.

380 34. Chan TD, Brink R. Affinity-based selection and the germinal center response. *Immunol Rev* 2012;
381 247: 11-23.

382 35. Ellebedy AH, Nachbagauer R, Jackson KJL, Dai YN, Han J, Alsoussi WB, *et al.* Adjuvanted H5N1
383 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses
384 in humans. *Proc Natl Acad Sci U S A* 2020; **117**: 17957-64.

- 385 36. Redjoul R, Le Bouter A, Parinet V, Fourati S, Maury S. Antibody response after third BNT162b2
  386 dose in recipients of allogeneic HSCT. *Lancet Haematol* 2021; 8: e681-3.
- 387 37. Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M, et al. Altered B-
- cell homeostasis and excess BAFF in human chronic graft-versus-host disease. *Blood* 2009; **113**: 386574.
- 390 38. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells
- after depletion with rituximab in patients with rheumatoid arthritis. *Arthritis Rheum* 2006; **54**: 613-20.
- 392 39. Saadoun D, Rosenzwajg M, Landau D, Piette JC, Klatzmann D, Cacoub P. Restoration of peripheral
  393 immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. *Blood* 2008; 111: 5334-41.
- 40. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, *et al.* Rituximab
  improves peripheral B cell abnormalities in human systemic lupus erythematosus. *Arthritis Rheum* 2004;
  50: 3580-90.

#### **397 FIGURE LEGENDS**

**Fig 1.** Immune response to SARS-CoV-2 mRNA vaccination. The scatter plot shows total immunoglobulin levels for healthy controls, immunodeficient patients and patients after anti-CD20 therapy or hematopoietic stem cell transplantation (HSCT). P is <0.001 between all groups calculated with the Kruskal-Wallis test and post hoc analysis. Lines are medians with interquartile range. The Plot was drawn with GraphPad Prism Version 9.2.0.332. 403 **Fig 2**. Correlation of antibody levels determined by Roche anti-SARS-CoV-2 S assay. (A) DiaSorin 404 SARS-CoV-2 TrimericS IgG. (B) Absolute number of B cells (CD19<sup>+</sup> cells). (C) Absolute number of 405 naïve B cells. Scatter plots indicate a linear regression line including a 95% confidence interval. In case 406 of A and B, regression line corresponds to transformed data using x=log((x+1)) and y=log((y+1)), 407 respectively.

408 Fig 3. Exploratory analyses estimating the number of naïve B cells and the interval to the last B-cell 409 depleting therapy required for a vaccination response. (A) The receiver operating characteristic (ROC) 410 analysis curve for naïve B cells differentiating stringent antibody response vs no or any vaccination 411 response in the whole study population (n=199) shows excellent discrimination. (B) A non-linear risk 412 model based on the observed risk of seroconversion was created to estimate the minimum number of 413 naïve B cells required for a stringent vaccination response. Independently, the best discriminatory cut-414 off (dashed line) was determined with the Youden's index from the ROC curve. Both models predict 415 that  $\geq 60$  naïve B cell per  $\mu$ l are required to generate a stringent vaccine response. (C) The ROC analysis 416 curve for the interval since the last B-cell depleting therapy up to 365 days (n=53) differentiating any 417 seroconversion vs no vaccination response. The optimal cut-off is an interval of 116 days or more.





